GSK and CureVac secure $740m payout in mRNA patent settlement
8th Aug 2025 07:36
(Sharecast News) - Drugmaker GSK said on Friday that it had reached a settlement, alongside CureVac, to resolve long-running patent litigation with BioNTech and Pfizer over mRNA-based COVID-19 vaccines.
Read moreLondon close: Stocks fall on Trump's latest tariffs, US jobs data
1st Aug 2025 17:37
(Sharecast News) - London stocks ended the week lower on Friday as investors reacted to a fresh wave of US tariffs and disappointing economic data from the United States.
Read moreLondon close: Stocks mixed on robust US data, earnings flurry
30th Jul 2025 17:15
(Sharecast News) - London equities ended Wednesday narrowly mixed as investors weighed stronger-than-expected US economic data against a wave of corporate earnings that failed to inspire.
Read moreGSK Q2 revenues grow, reiterates FY guidance
30th Jul 2025 07:36
(Sharecast News) - Drugmaker GSK said on Wednesday that Q2 revenues had grown as a strong specialty medicines performance drove sales and core operating profit growth.
Read moreLondon close: Stocks reverse gains to finish lower
28th Jul 2025 17:16
(Sharecast News) - London stocks ended lower on Monday, erasing earlier gains as investors reassessed the weekend's trade agreement between the United States and the European Union.
Read moreGSK and Hengrui unveil development deal worth up to $12bn
28th Jul 2025 07:17
(Sharecast News) - GSK has entered into a partnership with Chinese pharmaceutical outfit Hengrui Pharma to jointly develop up to 12 medicines, in a deal that could be worth up to $12bn.
Read moreLondon close: FTSE finishes week just shy of 9,000
18th Jul 2025 17:51
(Sharecast News) - London stocks ended higher on Friday, supported by a positive shift in investor sentiment following US consumer confidence data.
Read moreFDA votes against overall benefit/risk profile of GSK's multiple myeloma candidate at proposed dosage
18th Jul 2025 07:42
(Sharecast News) - Drugmaker GSK said on Friday that the US Food and Drug Administration's Oncologic Drugs Advisory Committee had voted against the overall benefit/risk profile of its relapsed/refractory multiple myeloma asset at the proposed dosage.
Read moreUS FDA approves new format of GSK's Shingrix
17th Jul 2025 09:21
(Sharecast News) - GSK announced on Thursday that it has received approval from the US Food and Drug Administration for a new prefilled syringe presentation of its shingles vaccine, Shingrix.
Read moreUS FDA to review GSK bid to extend use of respiratory virus drug
14th Jul 2025 07:03
(Sharecast News) - GSK said the US Food and Drug Administration has accepted an application for review to extend the indication of its Arexvy respiratory syncytial virus vaccine to adults aged 18-49 who are at increased risk.
Read moreEMA accepts marketing authorisation application for GSK's linerixibat
23rd Jun 2025 11:07
(Sharecast News) - GSK said on Monday that the European Medicines Agency has accepted its marketing authorisation application for linerixibat, an investigational treatment for cholestatic pruritus in patients with primary biliary cholangitis (PBC).
Read moreGSK hoping to expand Arexvy usage in Japan
20th Jun 2025 07:19
(Sharecast News) - Japanese regulators have accepted GSK's application to expand the use of its RSV vaccine, Arexvy, to the entire adult population.
Read moreGSK's RSV vaccine accepted for regulatory review by EMA
13th Jun 2025 07:01
(Sharecast News) - Drugmaker GSK said on Friday that its RSV vaccine, Arexvy, has been accepted for regulatory review by the European Medicines Agency to expand use in adults 18 years and older.
Read moreGSK's linerixibat to be reviewed by US FDA
2nd Jun 2025 07:40
(Sharecast News) - Drugmaker GSK revealed on Monday that a new drug application for its linerixibat asset had been accepted for review by the US Food and Drug Administration for use in cholestatic pruritus patients with primary biliary cholangitis.
Read moreGSK, Spero UTI drug trial ends early after meeting target
28th May 2025 13:19
(Sharecast News) - UK pharma giant GSK and its partner Spero Therapeutics on Wednesday said it had ended a late-stage trial of an experimental drug for complicated urinary tract infections early after it met its main target.
Read more